With the rising increase in bacteria and fungus resistant to current medications, companies are developing drugs that use novel mechanisms of action to fight the bugs. Read More
For the first time since 2011, the biopharma industry failed to complete a single initial public offering in the month of January, signifying a slowdown that began in the fourth quarter of 2015. Even the dismal year of 2012 had at least one IPO in January, compared with two in 2013, six in 2014 and five last year. Read More
The fact that approximately 95 percent of the 353 public biopharmaceutical companies tracked by the BioWorld Stock Report saw their share price values fall in January emphasizes just how brutal the equity markets have been so far this year. The prevailing conditions bring back memories of the chaotic markets experienced back in 2008 during the global financial meltdown. This time around the markets have been derailed by fears of a flagging global economy and a world drowning in an oversupply of crude oil with producers unwilling to turn off the tap. Read More
